janus kinase (JAK) inhibitor for COVID-19: living meta-analysis of clinical studies

Study explorer (study characteristics and results) method abbreviations pdf xlsx

display ongoing studies
Study	Ref.	Design	studied treatment	control treatment	patients	study risk of bias	sample sizes	Results
COVID-19 mild to moderate meta-analysis
Murugesan		RCT	tofacitinib	standard of care	COVID-19 mild to moderate	NA	50/50	inconclusive
Rodriguez-Garcia EUPAS34966		OBS	baricitinib	standard of care	COVID-19 mild to moderate	NA	62/50	no results
Cantini		OBS	baricitinib	standard of care	COVID-19 mild to moderate	critical	113/78	suggested	suggested 22.9-fold increase in hospital discharge but with a very low degree of certainty due to critical risk of bias

PE: primary endpoint; (a): to be demonstrated a result must be statistically significant on a primary endpoint (with multiplicity adjustment if necessary);
Study risk of bias assessed for the study primary endpoint(s) or the main endpoints in case of no formally defined primary endpoint(s).

Study explorer (study characteristics and results) method abbreviations pdf xlsx

COVID-19 mild to moderate meta-analysis